Whoop’s FDA gamble: Can wearables go beyond athletes?

Fourteen years after its founding, Whoop is making its boldest pivot yet—from elite athletes to everyday health. The Boston-based wearable, beloved by LeBron James and NFL stars, is now seeking FDA clearance for medical-grade applications, a move that could redefine its competition with Oura. According to TechCrunch, founder Will Ahmed envisions a device that doesn’t just track sleep and recovery but could one day "save your life."

Yet the path is fraught with hurdles. Unlike Oura, which has carved a niche in consumer wellness, Whoop’s FDA ambitions place it squarely in the crosshairs of regulatory scrutiny. Early signals suggest the company is exploring clinical use cases, such as detecting sleep apnea or irregular heart rhythms, but these remain in the exploratory phase. The FDA’s involvement, while a vote of confidence, also means slower timelines and higher stakes—any misstep could derail the company’s credibility in a market already skeptical of wearables’ medical claims.

The challenge isn’t just technical. Whoop must prove its algorithms can deliver actionable insights for non-athletes, a group with vastly different physiology and health risks than its current user base. Observational data from elite performers won’t translate seamlessly to a 50-year-old with hypertension or a sedentary office worker. The real test isn’t whether Whoop can track stress—it’s whether it can interpret it correctly for the average person.

For all the hype, Whoop’s venture into consumer medicine is still in its infancy. The company’s existing studies, while promising, are small-scale and lack the randomized controlled trials (RCTs) required for FDA approval. Its current FDA interactions are likely pre-submission discussions, meaning any medical claims remain years away from regulatory greenlight. Compare this to Oura, which already partners with research institutions on large-scale studies, including one tracking COVID-19 early symptoms with 100,000 participants.

The clinical relevance today? Zero. Whoop’s pivot won’t change patient care in 2024, but it could reshape the wearable industry’s future. If successful, it might bridge the gap between fitness trackers and medical devices, offering consumers a single tool for prevention and early detection. If it fails, it risks becoming another cautionary tale of overambition in the crowded wearables market.

What we don’t know is equally critical. Will the FDA demand gold-standard trials, or will it accept real-world evidence? Can Whoop’s hardware handle the computational demands of medical-grade monitoring, or will it need a complete redesign? And most importantly, will consumers even trust a device marketed as both a fitness coach and a lifesaver? The answers will determine whether Whoop’s bet pays off—or whether it becomes a footnote in the FDA’s growing scrutiny of wellness tech.